Developing the next-generation universal robotic system for minimal access surgery

Cambridge Medical Robotics is a private company developing the next-generation universal robotic system for minimal access surgery. 

Our vision is to make minimal access (or keyhole) surgery universally accessible and affordable by significantly expanding the range of procedures that can be performed robotically. CMR successfully completed preliminary cadaveric trials in May 2016, which will inform further cadaveric, animal and first-in-human trials.

CMR’s technology will transform the existing market for surgical robotics. Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025 ('Industry Forecast, Accuray Research').

Cambridge Medical Robotics has grown rapidly since incorporation in 2014 and has its headquarters in Cambridge, United Kingdom. The company achieved the registration of its Quality Management System to ISO 13485:2003 by Underwriters Laboratories LLC® (‘UL’) and the status as a UL Registered Firm in September 2015.

  1. Martin Frost

    Chief Executive Officer

  2. Luke Hares

    Technology Director

  3. Keith Marshall

    Engineering Director

  4. Paul Roberts

    Operations Director

  1. Martin Frost

    Chief Executive Officer

  2. Per Methi


  3. Robert Tansley


  4. Massimo Muzzi


  5. Erik Langaker

    Chairman of the Board

  6. Mark Slack

    Medical Advisory Board Chairman

  7. Reynir Indahl


Team culture

Our corporate culture is built on the basis of interdisciplinary collaborative working. 


Our history

Cambridge Medical Robotics Limited was incorporated in January 2014 with a vision to transform the way in which surgery is performed and make the acknowledged benefits of minimal access surgery universally accessible and affordable.

CMR has grown rapidly, moving to our facilities at Crome Lea Business Park in Cambridge in July 2014.

CMR logo


After the recently announced Series A financing, principal shareholders are ABB Technology Ventures, LGT Global Invest, Cambridge Innovation Capital and Escala Capital. Directors, management and a number of employees are also shareholders in the Company.